46 citations
,
December 1997 in “Cancer Nursing” In this study, patients receiving CHOP chemotherapy for aggressive non-Hodgkin's lymphoma reported a wide range of side effects, with all experiencing hair loss by cycle 3 and fatigue as a common issue.
September 2012 in “International Current Pharmaceutical Journal” In this study, CHOP chemotherapy for intermediate grade Non-Hodgkin's Lymphoma showed predictable toxicities but was generally well tolerated without treatment interruption among most patients.
January 2008 in “Hair transplant forum international” This summary describes the theme and location of the first International Live Surgery Workshop in Central Europe and provides no new research findings.
February 2020 in “Central Plains Medical Journal” In this study, combining thalidomide with CHOP treatment showed a significantly higher effective rate in treating peripheral T-cell lymphoma compared to CHOP alone, while both regimens were associated with similar levels of adverse reactions.
March 2025 in “OncoTargets and Therapy” This study found that in circulating tumor cells from non-invasive liquid biopsies, the GG genotype of the CYP3A5 A6986G affects longer disease-free survival in DLBCL patients, highlighting the significance of circulating biomarkers for prognostic evaluation.
